A Phase I Trial and Pharmacokinetic Study of a 24-hour Infusion of Trabectedin (Yondelis®, ET-743) in Children and Adolescents with Relapsed or Refractory Solid Tumors

BACKGROUND: The objectives of this phase I study were to determine the maximum tolerated dose (MTD), toxicity profile and pharmacokinetics of a 24-hour continuous intravenous infusion of trabectedin administered to children and adolescents with refractory or relapsed solid tumors. PROCEDURE: Patient...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Chuk, Meredith K., Aikin, Alberta, Whitcomb, Trish, Widemann, Brigitte C., Zannikos, Peter, Bayever, Eliel, Balis, Frank M., Fox, Elizabeth
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2012
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3442122/
https://ncbi.nlm.nih.gov/pubmed/22847981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24201
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items